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Objectives: To identify preferences of the Swedish public regarding antibiotic treatment characteristics and 
the relative weight of antibiotic resistance in their treatment choices. 
Methods: A questionnaire including a discrete choice experiment questionnaire was answered by 378 
Swedish participants. Preferences of the general public regarding five treatment characteristics (attributes) 
were measured: contribution to antibiotic resistance, cost, side effects, failure rate and treatment dura- 
tion. Latent class analysis models were used to determine attribute-level estimates and heterogeneity 
in preferences. Relative importance of the attributes and willingness to pay for antibiotics with a lower 
contribution to antibiotic resistance were calculated from the estimates. 
Results: All attributes influenced participants’ preferences for antibiotic treatment. For the majority of 
participants, contribution to antibiotic resistance was the most important attribute. Younger respon- 
dents found contribution to antibiotic resistance more important in their choice of antibiotic treatments. 
Choices of respondents with lower numeracy, higher health literacy and higher financial vulnerability 
were influenced more by the cost of the antibiotic treatment. Older respondents with lower financial 
vulnerability and health literacy, and higher numeracy found side effects to be most important. 
Conclusions: All attributes can be considered as potential drivers of antibiotic use by lay people. Findings 
also suggest that the behaviour of lay people may be influenced by concerns over the rise of antibiotic 
resistance. Therefore, stressing individual responsibility for antibiotic resistance in clinical and societal 
communication has the potential to affect personal decision making. 
© 2020 The Author(s). Published by Elsevier Ltd. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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. Introduction 
The rapid development of multi-drug-resistant bacteria is one 
f the most significant threats to public health globally [1] . In Eu- 
ope alone, the overall societal cost of antibiotic resistance (AR) has 
een estimated to result in extra healthcare costs and productivity 
osses of at least EUR 1.5 billion each year [2] , and to be the direct
ause of approximately 33,0 0 0 deaths each year [3] . ∗ Corresponding author. Address: Centre for Research Ethics and Bioethics, De- 
artment of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 
MC ingång A11, 751 22 Uppsala, Sweden. 
E-mail address: mirko.ancillotti@crb.uu.se (M. Ancillotti). 
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924-8579/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access articleAs antibiotic use is the main driver of AR [4 , 5] , a reduction in
he use of antibiotics is urgently required. The excessive use of an- 
ibiotics is also an issue in countries where antibiotics are prescrip- 
ion drugs (i.e. where they can only be dispensed to patients if 
here is a medical prescription). Patients can influence antibiotic 
rescription by showing positive expectations for antibiotic treat- 
ent, but it is also the case that prescribers can assume that pa- 
ients want to be prescribed these drugs. It has been shown that 
rescribers tend to prescribe antibiotics more often when they be- 
ieve that their patients expect them [6 , 7] . Antibiotic prescription 
s not determined merely by medical exigencies but is also heavily 
nfluenced by social factors. AR is a collective action dilemma; it 
an be mitigated only if sufficiently large numbers of people con- 
ribute to the common good and refrain from harmful behaviour. under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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or this reason, effective stewardship approaches should include 
ppropriately targeted awareness campaigns that can positively in- 
uence socially conscious citizens [8] . Research-funding agencies 
re calling for effective framing and communication of AR. In the 
ords of Wellcome Trust Director, Jeremy Farrar, ‘We can do all the 
cience and innovation we want but if we can’t take society with 
s, then we won’t land the science or the challenges, and we won’t 
ccess the maximum number of people [9] ’. Public campaigns for 
udicious use of antibiotics are often focused on awareness-raising 
s a behavioural tool. However, such campaigns have seldom been 
eveloped from an appraisal of public attitudes towards antibiotics 
nd AR [10–12] . The role that AR should be given in patient–doctor 
ommunication and in campaigns is debatable because the con- 
ept is difficult, and is a health threat not only for the individ- 
al but also (mostly) for the collective. The development of ef- 
ective communication requires knowledge in the following areas: 
i) What characteristics of antibiotic treatment drive antibiotic use 
y lay people? (ii) Can the behaviour of lay people be influenced 
y concerns over the rise of AR? As previous studies have mainly 
ocused on characteristics of antibiotics influencing patients’ and 
rescribers’ preferences or behaviour, the aim of the present study 
as to identify the preferences of the general public regarding an- 
ibiotic treatment characteristics, and to show the relative weight 
f AR in their treatment choices. 
. Materials and methods 
.1. Ethics 
This study adhered to Swedish research regulations and was ap- 
roved by Uppsala Regional Ethical Review Board (Dnr 2018/293). 
.2. Discrete choice experiment 
A discrete choice experiment (DCE) is a stated preference 
ethod, used widely and increasingly in health research [13] . The 
ethod provides participants with several hypothetical but real- 
stic choice sets. A DCE is used to elicit individuals’ preferences 
or a medical intervention, such as antibiotic treatment, under the 
ssumption that: (i) the treatment can be described by separate 
haracteristics (‘attributes’), which are further specified by variants 
alled ‘attribute levels’; and (ii) when showed alternative hypo- 
hetical treatment options that consist of different combinations 
f levels (i.e. choice tasks), individuals prefer the combination of 
ttributes and levels that gives them the highest utility [14] . Re- 
pondents choose multiple times between the alternatives and, by 
nalysing their choices, the relative importance of the attributes 
levels) can be determined and trade-offs can be calculated [15] . 
.3. Attributes and levels 
Attributes and levels were developed in adherence with 
ethodological standards [16 , 17] . The process is described below. 
.3.1. Literature review 
A literature search was conducted in PubMed (from 1999 to 
019) to identify key concepts in antibiotic use behaviour, and pro- 
uced 343 hits. An assessment of titles and abstracts was made. 
he criterion adopted was to include titles and abstracts indicat- 
ng that the document likely contained a description of character- 
stics of antibiotics influencing patients’ or prescribers’ preferences 
r behaviour. From the resulting 26 documents, 12 potential at- 
ributes were identified. 2 .3.2. Focus groups 
Twenty-three representatives of the general population (13 
omen and 10 men, mean age 38 years, age range 20–81 years) 
articipated in four focus group discussions. Participants were re- 
ruited through an area-based approach and purposive sampling, 
iming to create groups as heterogeneous as possible with re- 
ard to gender, age and education level. Data were collected until 
aturation was reached. Nominal group process (NGP) techniques 
ere employed to determine features that would drive partici- 
ants’ decision-making between different antibiotic treatment op- 
ions. NGP is a method encompassing a number of steps and tech- 
iques to explore the qualitative and quantitative elements, pat- 
erns and structure of a healthcare issue under preliminary investi- 
ation [18] . Each group generated a ranking of the most important 
ntibiotic features. After adopting uniform terminology to elimi- 
ate different formulations for the same attribute, seven additional 
otential attributes were identified. 
.3.3. Attribute features checklist 
All 19 potential attributes (12 from the literature review and 
even from the focus groups) were tested against a checklist of de- 
irable attribute features, based on the methodological literature 
n DCEs and the researchers’ experience [16 , 17] . The desirable fea- 
ures of the attributes for inclusion in the final list of attributes 
ere: realistic, plausible, tradable, clear and unambiguous, distinc- 
ively different from others, comprehensive, not a proxy for utility, 
nlikely to dominate, and relevant to respondent’s choice. 
.3.4. Stakeholder interviews and refinement 
Interviews with stakeholders (two general practitioners, a nurse 
nd a pharmacist) were held to discuss the attributes, levels and 
he whole questionnaire. The research team discussed the results 
f the interviews until consensus was reached. The number of at- 
ributes was kept as low as possible to increase response accuracy 
19] . Table 1 presents the attributes and levels as described in the 
nstruction section of the DCE. 
.4. DCE design 
A Bayesian D-efficient design was created using Ngene 1.0 
ChoiceMetrics, Sydney, Australia, 2011) to estimate a standard 
ulti-nomial logit (MNL) model, based on a main-effects utility 
unction. The prior preference information needed for the design 
as based on best guesses from the literature and expert opin- 
ons. Choice tasks consisted of two unlabelled antibiotic alterna- 
ives: ‘Antibiotic A’ and ‘Antibiotic B’ (see Fig. 1 ). 
In the pre-testing phase, peer debriefing and think-aloud ( n = 4) 
ethods were used [20] . Forty-four respondents from the general 
opulation took part in a pilot test run in February 2019. The pi- 
ot used the same recruitment method and research population as 
he final survey. In the pilot phase, the whole questionnaire was 
ested to see whether correct wording was used and if the re- 
earch population could understand the attributes, levels, informa- 
ion and choice tasks. Data were analysed using MNL models, and 
stimates were used as priors for the final DCE design. The final 
ayesian D-efficient design consisted of 48 unique choice tasks di- 
ided over three blocks of 16 choice tasks to which respondents 
ere assigned at random. 
.5. Questionnaire 
Light House Studio 9.6.1 (Sawtooth Software, Provo, UT, USA) 
as used to design the questionnaire and conduct the web-based 
urvey in April 2019. The questionnaire had three sections. 
The first section comprised sociodemographic and background 
uestions, including age, gender, highest attained educational level, 
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Table 1 
Attributes (bold) and attribute levels (italic) as described in the survey. 
Contribution to AR Bacteria that can withstand an antibiotic treatment are antibiotic-resistant bacteria. The main cause of resistance is treatment with 
antibiotics. AR is a serious and growing public health problem. It results in longer care times, higher care costs and an increased risk of complications in 
infection. The contribution to AR of the antibiotic treatments you choose is: 
Low 15,000 cases per year: in 10 years, the number of cases in Sweden would remain the same. 
Medium 30,000 cases per year: in 10 years, the number of cases in Sweden would double. 
High 70,000 cases per year: in 10 years, the number of cases in Sweden would more than quadruple. 
Treatment duration You must take three tablets a day throughout the treatment period prescribed by your doctor. 
3 days 
7 days 
14 days 
Side effects All medicines have side effects, including antibiotics. As they not only kill harmful but also beneficial bacteria in the body, they can cause 
mild-to-moderate side effects such as nausea, stomach upset, headache and tiredness. In the choice situations, it is stated how likely the antibiotic treatment is 
to cause side effects. 
1% (1 in 100 people taking this antibiotic get side effects, 99 do not get side effects) 
5% (5 in 100 people taking this antibiotic get side effects, 95 do not get side effects) 
10% (10 in 100 people taking this antibiotic get side effects, 90 do not get side effects) 
20% (20 in 100 people taking this antibiotic get side effects, 80 do not get side effects) 
Treatment failure An antibiotic treatment can fail to treat an infection for many reasons. If a treatment fails, it means that you have to be treated with another 
course of antibiotics. 
5% (5 out of 100 people need a further course of antibiotics) 
10% (10 out of 100 people need a further course of antibiotics) 
15% (15 out of 100 people need a further course of antibiotics) 
20% (20 out of 100 people need a further course of antibiotics) 
Cost Antibiotic treatments are not reimbursed and you have to pay out-of-pocket. 
€10 
€25 
€40 
€100 
AR, antibiotic resistance. 
Fig. 1. Example choice task and hover box. 
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ccupation and financial vulnerability. The latter describes the 
ndividual’s ability to recover from sudden financial shocks. Re- 
pondents answered whether they had experienced trouble reach- 
ng the end of the month or not in the past year, and if they
ould afford an unexpected expense. The first section further 
sked for self-reported health status using a five-point Likert scale 
rom very good to very poor. Finally, experience of and knowl- 
dge about antibiotics were tested (two questions on antibiotic 
se and two related to AR), and two validated subjective rat- 
ng scales were used to determine the respondent’s health liter- 
cy (S-CCHL: the Communicative and Critical Health Literacy Scale 
Swedish version) and numeracy (SNS-3: the three-item ver- 3 ion of the Subjective Numeracy Scale) [21 , 22] . Health literacy is 
 measure of the ability to access, understand, appraise and ap- 
ly health-related information. Numeracy refers to the ability to 
pply and manipulate numerical concepts. The S-CCHL consists 
f five items on a five-point Likert scale from ‘never (1)’ to ‘al- 
ays (5)’. The SNS-3 consists of three items on a six-point Likert 
cale from ‘not good at all/never (1)’ to ‘extremely good/very of- 
en (6)’. In both scales, an overall level was calculated for each re- 
pondent. In terms of their level of health literacy and numeracy, 
espondents who scored 1/2 were classed as ‘inadequate’; those 
ho had at least one score of 3 in the S-CCHL and 3/4 in the
NS-3 were classed as ‘problematic’; and those who consistently 
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cored 4/5 in the S-CCHL and 5/6 in the SNS-3 were classed as 
sufficient’. 
The second section comprised information about the DCE and 
he set of 16 DCE choice tasks. As individuals’ understanding of 
edical probabilities varies [23] , a multi-faceted approach was 
dopted by integrating words, fractions, percentages and icon ar- 
ays to describe attributes and levels wherever applicable. Partici- 
ants in this study were asked to imagine that they had a bacterial 
nfection and that the doctor prescribed antibiotics to avoid com- 
lications. While completing the choice tasks, respondents could 
lace the mouse over the attribute or level and a hover box would 
ppear as a pop-up window (see Fig. 1 ). In the third section, con-
luding questions aimed to assess any difficulties experienced and 
he length of the questionnaire, both on a five-point Likert scale, 
nd an optional comments field was included. 
.6. Study sample 
An online sample from the Swedish general population, nation- 
lly representative in terms of age, gender and geographical region, 
as recruited via Dynata, a commercial survey sample provider. 
alculating the optimal DCE sample size is complicated by the fact 
hat it depends on the true values of the unknown parameters esti- 
ated in the discrete choice models. However, there is a generally 
ccepted rule of thumb for calculating sample size [Eq. (1)] : 
ample size > 
500 l 
T A 
(1) 
The sample size required depends on the number of choice sit- 
ations ( T ), the number of attributes in a choice task ( A ), and the
ighest number of levels ( l ). This survey included 48 choice tasks 
ith two alternatives, and the overdue level was 4. Therefore, this 
uestionnaire required at least 63 respondents (500 ∗4/16 ∗2 = 62.5) 
o estimate the main effects alone. As three blocks were included 
n the design, there was a need for at least 189 respondents (63 x 
 = 189). To be able to identify differences in preferences (i.e. pref- 
rence heterogeneity) and to perform subgroup analysis, there was 
 need for a larger sample. Based on the DCE design, the pilot test, 
nd using current insights related to optimal sample sizes for DCE 
tudies [13] , a sample size of 350 respondents was deemed to be 
ufficient. The inclusion criteria were 18–65 years of age and profi- 
iency in the Swedish language. Respondents were excluded if they 
ould not take antibiotics (e.g. allergic individuals). 
.7. Statistical analysis 
All variables were analysed using descriptive statistics in Statis- 
ical Package for the Social Sciences (SPSS) Version 25 (IBM Corp., 
rmonk, NY, USA). Choice data were analysed using Nlogit 5.0 
Econometric Software Inc., Plainview, NY, USA, 2012). 
Latent class analysis (LCA) models were used to analyse choice 
ata. LCA assumes that respondents differ with respect to their 
references. The classes of preferences are latent because who be- 
ongs to which class is not determined a priori. Instead, class mem- 
ership is expressed as class probabilities that may depend on re- 
pondents’ characteristics. What is determined by the researcher is 
he number of classes, based on the model fit (Aikake information 
riterion, Bayesian information criterion, pseudo- R 2 ) and sound in- 
erpretation of classes [15] . The modelling procedure resulted in a 
hree-class model based on the utility function in Eq. (2) . 
 rta | c = β1 | c C ontrib toA R medium rta | c + β2 | c C ontrib toA R high rta | c 
+ β3 | c T reatment dura t 7 days rta | c 
+ β4 | c T reatment d ura t 14 days rta | c + β5 | c Sid e e f f ect s 5% rta | c 
+ β6 | c Side e f f ect s 10% rta | c + β7 | c Side e f f ect s 20% rta | c 
+ β8 i | c F ailure rat e rta | c + β9 i | c Cos t rta | c + ε (2) 4 In Eq. (2) , U represents the observable utility that a respondent 
 belonging to class c selected alternative a in choice question t ; 
nd β1 – β9 are variable weights (coefficients) associated with 
ach attribute of the DCE. Failure rate and cost were considered 
s linear attributes, whereas contribution to AR, treatment dura- 
ion and side effects were categorical and therefore dummy coded. 
he reference levels for contribution to AR, treatment duration and 
ide effects were low, 3 days and 1%, respectively. A significant co- 
fficient ( P ≤0.05) indicates that the attribute or level has a signif- 
cant impact on antibiotic treatment preferences. A significant at- 
ribute estimate within a certain class indicates that this attribute 
ontributes to the decision-making process of respondents who be- 
ong to that class. The sign of the coefficient reveals whether this 
mpact has a positive or negative effect on utility. 
After fitting the utility function, a class assignment model was 
stimated. Potential explanatory variables were tested for a signif- 
cant contribution to the class assignment model. The final class 
ssignment resulted in the utility function in Eq. (3) : 
 rta | c = β1 Ag e rta | c + β2 F inancial v u ln erabilit y rta | c 
+ β3 Heal th l iterac y rta | c + β4 Numerac y rta | c (3) 
ignificant estimates in Eq. (3) indicate that the variables con- 
ribute to the class assignment. For instance, if health literacy is 
ositive and significant for Class 1, respondents with sufficient 
ealth literacy are more likely to belong to Class 1. 
The attribute with the highest relative importance score (RIS) 
n each class is most decisive in the choice of antibiotic treatment. 
o estimate RIS, the difference between the largest and the small- 
st attribute level estimate was calculated for each attribute. An 
mportance score of 1 was given to the attribute with the largest 
ifference value. All other RISs was calculated by dividing the dif- 
erence value by the largest difference value, which gave the rel- 
tive distance of each attribute to the most important attribute. 
IS values were calculated separately for each of the classes in the 
odel. 
Marginal willingness to pay (WTP) values were determined for 
ontribution to AR. To calculate respondents’ WTP, the estimate of 
ost attribute was used as a measure of the marginal utility of 
oney. The ratio of the estimates of contribution to AR and cost 
as calculated to elicit respondents’ WTP for contribution to AR. 
. Results 
.1. Study population 
In total, 415 individuals completed the survey, 37 (8.9%) of 
hom were subsequently excluded as they completed the sur- 
ey in less than 6 min. The time needed was estimated to be 12 
in. To enhance quality, a 50% cut-off was chosen and data were 
leared accordingly (e.g. the rule of thumb in commercial surveys 
s 30%). Of the 378 respondents included in the final cohort, 55% 
ere women. The mean age of respondents was 43 years. In to- 
al, 51.9% reported a high educational level, and sufficient health 
iteracy and numeracy were reported by 46.6% and 23.3% of re- 
pondents, respectively. High financial vulnerability was reported 
y 33.6% of respondents, and 10.8% of the respondents reported 
eing unemployed. There were four questions to test knowledge, 
nd while approximately 66% of respondents answered the antibi- 
tic use questions correctly, they were less knowledgeable about 
R (6.1% and 29.1% answered correctly, respectively). The detailed 
ociodemographic characteristics are presented in Table 2 . 
.2. Preferences for antibiotic treatment 
All attributes showed a significant estimate, which indi- 
ates that each attribute contributed to the decision process of 
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Table 2 
Sociodemographic characteristics of respondents 
Respondents ( n = 378) 
Mean SD 
Age 18–65 years 43.3 13.5 
n (%) 
Women 208 55.0 
Health 
Bad 44 11.6 
Moderate 113 29.9 
Good 221 58.5 
Education 
Low 26 6.9 
Medium 156 41.2 
High 196 51.9 
Tertiary health education 39 10.3 
Health literacy 
Inadequate 41 10.8 
Problematic 161 42.6 
Sufficient 176 46.6 
Numeracy 
Inadequate 108 28.6 
Problematic 182 48.1 
Sufficient 88 23.3 
Occupation 
Employed (permanent, temporary, self-employed) 248 65.6 
Students 36 9.5 
Retired 34 9 
Unemployed 41 10.8 
On disability living allowance, sick leave or other 19 5.0 
Financial vulnerability 
High 127 33.6 
Medium 105 27.8 
Low 146 38.6 
Antibiotic use experience 
Yes 332 87.8 
Never 20 5.3 
Don’t know 26 6.9 
Knowledge 
Antibiotics are effective against (multiple responses): 
(correct) Bacteria 257 68.0 
Viruses, All microbes, Don’t know 121 32.0 
Antibiotics are effective against influenza (single response): 
(correct) Disagree 244 64.6 
Agree, Don’t know 134 35.4 
Human body becomes resistant to antibiotics (single response): 
(correct) Disagree 23 6.1 
Agree, Don’t know 355 93.9 
AR spreads through contact with (multiple responses): 
(correct) Human carriers, Animal carriers, Infected surfaces 110 29.1 
Don’t know or only 1 or 2 of the answers above 268 70.9 
SD, standard deviation. 
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espondents regarding choices about taking antibiotics. The esti- 
ates for the attribute levels are presented in Table 3 . In gen- 
ral, participants preferred antibiotics with a low contribution to 
R compared with antibiotics with a greater contribution to AR. 
dditionally, participants preferred medium-course treatment du- 
ations (7 days) over long-course (14 days) and short-course (3 
ays) treatment duration. The lowest risk of side effects (1%) was 
he preferred option. The negative signs for failure rate and cost 
ndicate that participants preferred treatments with a lower failure 
ate and a lower price. 
.3. Relative importance of the attributes and willingness to pay 
Considering the preferences of respondents overall, contribution 
o AR was the most important attribute, closely followed by cost 
nd then side effects, failure rate and treatment duration. How- 
ver, respondents in the three classes reported different prefer- 
nces with respect to antibiotic treatment, which indicates prefer- 5 nce heterogeneity (see Table 3 ). Respondents in Class 1 found cost 
o be the most important attribute, followed by contribution to AR, 
reatment duration, failure rate and side effects. For respondents in 
lass 2, contribution to AR was the most important, followed by 
ost, side effects, treatment duration and failure rate. For respon- 
ents in Class 3, side effects was the most important, followed by 
ontribution to AR, cost, failure rate and treatment duration (see 
ig. 2 ). 
Respondents with lower numeracy, and higher financial vul- 
erability and health literacy were more likely to belong to Class 
. Younger respondents had a greater likelihood of belonging to 
lass 2. Older respondents with lower financial vulnerability and 
ealth literacy, and higher numeracy were more likely to belong to 
lass 3. 
Respondents’ WTP for an antibiotic contributing the least to 
R was: 389 SEK (approximately €36.50) to have low instead of 
edium contribution to AR, and 940 SEK (approximately €88) to 
ave low instead of high contribution to AR. 
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Table 3 
Preferences for antibiotic treatment based on latent class analysis 
Class 1 Class 2 Class 3 
Estimate SE RI Estimate SE RI Estimate SE RI 
Contribution to AR 2 1 2 
Low (ref.) 
Medium -0.49 ∗∗∗ 0.11 -1.69 ∗∗∗ 0.12 -0.10 0.09 
High -0.81 ∗∗∗ 0.19 -4.21 ∗∗∗ 0.24 -0.51 ∗∗∗ 0.14 
Treatment duration 3 4 5 
3 days (ref.) 
7 days 0.15 0.10 0.11 0.11 0.05 0.08 
14 days -0.39 ∗∗∗ 0.10 -0.25 ∗∗ 0.11 -0.17 ∗∗ 0.08 
Risk of side effects 5 3 1 
1% (ref.) 
5% -0.13 0.12 -0.24 ∗ 0.13 -0.33 ∗∗∗ 0.10 
10% -0.01 0.13 -0.20 0.14 -0.77 ∗∗∗ 0.10 
20% -0.23 0.16 -0.71 ∗∗∗ 0.16 -1.59 ∗∗∗ 0.13 
Failure rate (linear) -0.17 0.14 4 -0.59 ∗∗∗ 0.14 5 -0.95 ∗∗∗ 0.12 4 
Cost (linear) -0.43 ∗∗∗ 0.03 1 -0.15 ∗∗∗ 0.02 2 -0.05 ∗∗∗ 0.02 3 
Class probability model 
Constant 1.44 ∗ 0.83 1.05 0.76 
Age -0.01 0.01 -0.03 ∗∗∗ 0.01 
Financial vulnerability -0.42 ∗∗ 0.18 0.05 0.17 
Health literacy 0.58 ∗∗ 0.24 0.26 0.23 
Numeracy -0.62 ∗∗∗ 0.22 0.08 0.20 
Average class probability 0.33 0.38 0.29 
AR, antibiotic resistance; RI, relative importance. 
∗ P < 0.10 
∗∗ P < 0.05 
∗∗∗ P < 0.01. 
Fig. 2. Relative importance of the attributes stratified by class. Values reflect the relative distance of all attributes to the most important attribute on a scale from 0 to 1. 
Contrib to AR, contribution to antibiotic resistance. 
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. Discussion 
To the authors’ knowledge, this is the first DCE to investigate 
he preferences of lay people for antibiotic treatments. Previous 
CEs have focused on either prescribers or patients [24–28] . The 
urrent study showed that all attributes of antibiotic treatments 
nfluenced respondents’ preferences, and can therefore be consid- 
red as potential drivers of antibiotic use by lay people. The find- 
ng that the majority of respondents thought that contribution to 
R was the most important attribute suggests that the behaviour 
f lay people could be influenced by concerns over the rise of AR. 
t is important to stress that this attribute was explained to peo- 6 le as a collective threat and not as a problem to the individual. 
hese results are consistent with a recent Swedish study in which 
he majority of participants expressed their willingness to volun- 
arily abstain from using antibiotics out of concern over AR [29] . 
he importance of contribution to AR was quantified financially, 
nd respondents were willing to pay €36.50 for switching from an 
ntibiotic treatment with medium contribution to AR to a treat- 
ent with low contribution to AR, and €88 to switch from an an- 
ibiotic treatment with high contribution to AR to a treatment with 
ow contribution to AR. Considering that the cost attribute (used 
or calculating WTP) was operationalized and framed as out-of- 
ocket costs (not covered by health insurance), the numbers are 
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uite high and could be of interest for policy makers consider- 
ng financial incentives and disincentives as a means of influencing 
ealth-related behaviour. 
Results showed heterogeneity in preferences, which means that 
espondents weighed the attributes of antibiotic treatment in dif- 
erent ways. Respondents with low numeracy and high financial 
ulnerability were more influenced in their decision-making by the 
ost of the antibiotic (Class 1). Younger respondents were more 
oncerned about their contribution to AR (Class 2), and older re- 
pondents were more concerned about side effects (Class 3). These 
esults could facilitate the segmentation and consequent develop- 
ent of tailored messages. 
The finding that younger respondents were more concerned 
bout contribution to AR is in line with previous research. A 
wedish study on the general population’s knowledge and atti- 
udes towards antibiotic use and AR found that younger people 
ere more likely than older people to show an appropriate atti- 
ude towards antibiotic accessibility and infection prevention [30] . 
esearch conducted in Italy, however, gave the opposite result, 
ith younger respondents being more inclined to take an antibi- 
tic without a prescription [31] . This suggests that regional and 
ultural differences need to be acknowledged. Regarding financial 
ulnerability, results were as expected; namely, that respondents 
ith higher financial vulnerability were more influenced by the 
ost attribute. Research on socio-economic determinants of outpa- 
ient antibiotic use suggest that, from an economic point of view, 
ntibiotics are normal goods. This implies that individual finan- 
ial health, which typically contributes to greater access to med- 
cal care, also influences antibiotic use [32 , 33] . A study of 17 Euro-
ean countries found that higher antibiotic prices were associated 
ith lower antimicrobial consumption. Purchasing antibiotics out- 
f-pocket instead of under total or partial reimbursement was also 
ssociated with lower antimicrobial consumption [33] . Numeracy 
s relevant to the present study because respondents needed to 
nterpret and value risk information (risk of side effects and fail- 
re rate). Low numeracy is generally associated with biased medi- 
al decisions [34] . The fact that respondents with lower numeracy 
ave the least importance to failure rate and side effects may be a 
onsequence of their difficulties in interpreting and understanding 
he risk attributes. Previous research highlighted that information 
hich is not well understood is more likely to be neglected or un- 
ervalued [35 , 36] . Although significant, it is difficult to explain the 
ole of health literacy in the class probability model, and further 
esearch into this variable would benefit greater understanding of 
hese outcomes. 
Seven days was the most preferred level for treatment duration, 
nd this is probably motivated by respondents’ familiarity with 7- 
ay treatment courses and/or the idea that 3 days of treatment 
ay not be enough to eradicate the infection. Previous research 
howed positive attitudes towards short-course treatments among 
atients, but has also stressed the importance of reassurance that 
hort courses are effective [37 , 38] . 
Respondents showed poor knowledge about AR. In particular, 
nly 6.1% of respondents disagreed with the statement, ‘The hu- 
an body can become resistant to antibiotics, giving free space to 
acteria’. In a previous study of the Swedish public [30] , 12% an- 
wered ‘no’ (correctly) to the statement, ‘People can become resis- 
ant to antibiotics’, which is also a low score. By maintaining the 
elief that it is one’s own body that becomes resistant to antibi- 
tics, and not the bacteria, people may see the problem of AR as 
eing strictly individual and fail to understand the threat posed to 
ublic health. This belief is worrying but not very surprising [39] . 
All results were in line with the expected directions of the esti- 
ates and provide support for the theoretical internal validity of 
he model. Nevertheless, this study was subject to some limita- 
ions. To investigate the robustness of the results, lexicographical 7 reference assessment was performed to detect participants with 
on-compensatory decision-making strategies. Tests were run for 
eft–right bias (always choosing the alternative on the left or the 
ight) and gave negative results. As participants were part of a 
ixed panel recruited by a commercial survey sample provider, 
t was not possible to calculate the response rate. With regards 
o external validity, as for all DCEs, there is a risk of hypothetical 
ias (i.e. that the results may not reflect actual behaviour). There is 
o possibility to compare the present results with revealed prefer- 
nce studies. However, studies investigating the predictive value of 
CEs in public health have shown accuracy between 80% and 93% 
40 , 41] . 
. Conclusion 
All antibiotic treatment attributes (contribution to AR, treat- 
ent duration, side effects, treatment failure and cost) can be con- 
idered as potential drivers of antibiotic use by lay people. The 
ndings suggest that concerns over rising resistance to antibiotics 
an influence people’s behaviour. Therefore, stressing individual re- 
ponsibility for AR in clinical and societal communication has the 
otential to impact personal decision-making. However, consider- 
ng that the concept and mechanisms of AR are still obscure to 
he majority, communication including AR could be effective only 
f adequate information is provided. The risk of acquiescing to any 
ind of AR misconception is that it may induce non-judicious an- 
ibiotic use. If patients are informed and feel responsible, they may 
push’ less for an antibiotic prescription and, perhaps more impor- 
antly, reduce prescribers’ perception that patients expect an an- 
ibiotic treatment prescription. 
The finding that cost was the second most important attribute, 
ogether with the rather high WTP for antibiotics that contribute 
ess to AR, suggest that changing the price of antibiotics may in- 
uence consumption behaviour. However, caution is warranted be- 
ause the group whose preferences were mainly influenced by the 
ost attribute showed financial vulnerablility and low numeracy. 
herefore, the risk involved by policy aiming at contrasting exces- 
ive use of antibiotics through financial incentives and disincen- 
ives is that it may hinder access to treatment and cause health 
nequalities. 
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